Niemann-Pick Disease, Type C Clinical Trial
Official title:
Longitudinal Study of Cognition With Niemann-Pick Disease, Type C
Niemann-Pick Disease, Type C (NPC) is a rare neurodegenerative disorder with a wide clinical spectrum and variable age of onset. Classically, children with NPC demonstrate neurological dysfunction with cerebellar ataxia (an inability to coordinate balance, gait, extremity and eye movements), dysarthria (difficulty speaking), seizures, vertical gaze palsy (ability to move eyes in the same direction) motor impairment, dysphagia (trouble swallowing), psychotic episodes, and progressive dementia. There is no curative treatment for NPC and it is a lethal disorder. The purpose of this protocol is to obtain both baseline and rate of progression data on a clinical and biochemical markers that may later be used as outcome measures in a clinical trial. Specifically, this study will examine and characterize the longitudinal progression of neurocognitive symptoms of NPC with the goal of identifying early markers of disease progression that may be utilized in later trials to evaluate treatment efficacy.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03759639 -
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
|
Phase 2 | |
| Withdrawn |
NCT04189601 -
Complement Activation in the Lysosomal Storage Disorders
|
||
| Completed |
NCT02435030 -
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C
|
N/A | |
| Completed |
NCT02534844 -
VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05588167 -
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
|
||
| Withdrawn |
NCT03687476 -
Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease
|
Phase 2 | |
| Enrolling by invitation |
NCT05368038 -
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
|
||
| Terminated |
NCT00668564 -
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
|
Phase 2 | |
| Active, not recruiting |
NCT05163288 -
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
|
Phase 3 | |
| Active, not recruiting |
NCT02612129 -
Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03471143 -
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
|
Phase 1/Phase 2 | |
| Terminated |
NCT04958642 -
Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease
|
Phase 2/Phase 3 | |
| Terminated |
NCT03879655 -
Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1
|
Phase 2/Phase 3 | |
| Completed |
NCT00975689 -
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01306604 -
Biomarker for Niemann Pick Type C Disease (BioNPC)
|
||
| Recruiting |
NCT00344331 -
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
|
||
| Active, not recruiting |
NCT05758922 -
Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
|
Phase 2 | |
| Completed |
NCT03910621 -
Safety and Efficacy of Miglustat in Chinese NPC Patients
|
Phase 4 | |
| Available |
NCT04316637 -
Early Access Program With Arimoclomol in US Patients With NPC
|